Blood test for breast cancer survivors at risk of recurrence
Treatments studied
Part of Cancer, Skin clinical trials.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have triple-negative breast cancer (where the cancer cells do not have receptors for estrogen, progesterone, or too much HER2 protein).
- Your cancer was stage 2 or 3 and you completed chemotherapy before surgery, but some cancer remained after surgery.
- Your latest scans show no signs that the cancer has spread to other parts of your body.
- Your medical team has tissue samples from your diagnosis or surgery that can be used for testing.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.